These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

772 related items for PubMed ID: 32747298

  • 1. Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19+ malignancy in a mouse model.
    Liu Q, Xu Y, Mou J, Tang K, Fu X, Li Y, Xing Y, Rao Q, Xing H, Tian Z, Wang M, Wang J.
    Cytotherapy; 2020 Oct; 22(10):552-562. PubMed ID: 32747298
    [Abstract] [Full Text] [Related]

  • 2. CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia.
    Yang N, Zhang C, Zhang Y, Fan Y, Zhang J, Lin X, Guo T, Gu Y, Wu J, Gao J, Zhao X, He Z.
    J Transl Med; 2024 Mar 13; 22(1):274. PubMed ID: 38475814
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
    Oelsner S, Friede ME, Zhang C, Wagner J, Badura S, Bader P, Ullrich E, Ottmann OG, Klingemann H, Tonn T, Wels WS.
    Cytotherapy; 2017 Feb 13; 19(2):235-249. PubMed ID: 27887866
    [Abstract] [Full Text] [Related]

  • 5. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
    Xu Y, Liu Q, Zhong M, Wang Z, Chen Z, Zhang Y, Xing H, Tian Z, Tang K, Liao X, Rao Q, Wang M, Wang J.
    J Hematol Oncol; 2019 May 16; 12(1):49. PubMed ID: 31097020
    [Abstract] [Full Text] [Related]

  • 6. Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth.
    Oelsner S, Waldmann A, Billmeier A, Röder J, Lindner A, Ullrich E, Marschalek R, Dotti G, Jung G, Große-Hovest L, Oberoi P, Bader P, Wels WS.
    Int J Cancer; 2019 Oct 01; 145(7):1935-1945. PubMed ID: 30860598
    [Abstract] [Full Text] [Related]

  • 7. CCR7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma.
    Schomer NT, Jiang ZK, Lloyd MI, Klingemann H, Boissel L.
    Cytotherapy; 2022 Aug 01; 24(8):827-834. PubMed ID: 35400595
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer.
    Montagner IM, Penna A, Fracasso G, Carpanese D, Dalla Pietà A, Barbieri V, Zuccolotto G, Rosato A.
    Cells; 2020 Jun 02; 9(6):. PubMed ID: 32498368
    [Abstract] [Full Text] [Related]

  • 11. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells.
    Jiang H, Zhang W, Shang P, Zhang H, Fu W, Ye F, Zeng T, Huang H, Zhang X, Sun W, Man-Yuen Sze D, Yi Q, Hou J.
    Mol Oncol; 2014 Mar 02; 8(2):297-310. PubMed ID: 24388357
    [Abstract] [Full Text] [Related]

  • 12. Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells.
    Shiozawa M, Chang CH, Huang YC, Chen YC, Chi MS, Hao HC, Chang YC, Takeda S, Chi KH, Wang YS.
    BMC Immunol; 2018 Aug 03; 19(1):27. PubMed ID: 30075754
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. TGF-β/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma.
    Noh KE, Lee JH, Choi SY, Jung NC, Nam JH, Oh JS, Song JY, Seo HG, Wang Y, Lee HS, Lim DS.
    Int J Mol Sci; 2021 Aug 13; 22(16):. PubMed ID: 34445415
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy.
    Guo S, Lei W, Jin X, Liu H, Wang JQ, Deng W, Qian W.
    Blood Adv; 2024 Jun 11; 8(11):2635-2645. PubMed ID: 38564778
    [Abstract] [Full Text] [Related]

  • 17. Cytokines induced memory-like NK cells engineered to express CD19 CAR exhibit enhanced responses against B cell malignancies.
    He B, Mai Q, Pang Y, Deng S, He Y, Xue R, Xu N, Zhou H, Liu X, Xuan L, Li C, Liu Q.
    Front Immunol; 2023 Jun 11; 14():1130442. PubMed ID: 37207215
    [Abstract] [Full Text] [Related]

  • 18. Transferrin epitope-CD19-CAR-T cells effectively kill lymphoma cells in vitro and in vivo.
    Valentine M, Li L, Zhou H, Xu S, Sun J, Liu C, Harto H, Berahovich R, Golubovskaya V, Wu L.
    Front Biosci (Landmark Ed); 2020 Jan 01; 25(2):270-282. PubMed ID: 31585889
    [Abstract] [Full Text] [Related]

  • 19. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
    Kloess S, Oberschmidt O, Dahlke J, Vu XK, Neudoerfl C, Kloos A, Gardlowski T, Matthies N, Heuser M, Meyer J, Sauer M, Falk C, Koehl U, Schambach A, Morgan MA.
    Hum Gene Ther; 2019 Apr 01; 30(4):381-401. PubMed ID: 30734584
    [Abstract] [Full Text] [Related]

  • 20. Preclinical Evaluation of CRISPR-Edited CAR-NK-92 Cells for Off-the-Shelf Treatment of AML and B-ALL.
    Ureña-Bailén G, Dobrowolski JM, Hou Y, Dirlam A, Roig-Merino A, Schleicher S, Atar D, Seitz C, Feucht J, Antony JS, Mohammadian Gol T, Handgretinger R, Mezger M.
    Int J Mol Sci; 2022 Oct 24; 23(21):. PubMed ID: 36361619
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.